Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Molecular responses to immune checkpoint blockade in glioblastoma.

Ito H, Nakashima H, Chiocca EA.

Nat Med. 2019 Mar;25(3):359-361. doi: 10.1038/s41591-019-0385-7. No abstract available.

PMID:
30842671
2.

CD103+ Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model.

Miao X, Chen Y, Hao K, Zheng M, Chen B, Li K, Wang Y, Zhang W, Zhang Y, Mou X, Jiang S, Wang Z.

Oncol Res. 2018 Mar 5;26(2):173-182. doi: 10.3727/096504017X14841698396865. Epub 2017 Jan 20.

PMID:
28109087
3.

Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.

Yeo AT, Charest A.

J Cell Biochem. 2017 Sep;118(9):2516-2527. doi: 10.1002/jcb.25948. Epub 2017 May 3. Review.

4.

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.

Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J.

J Exp Clin Cancer Res. 2019 Feb 18;38(1):87. doi: 10.1186/s13046-019-1085-3. Review.

5.

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ.

Cancer Immunol Res. 2016 Feb;4(2):124-35. doi: 10.1158/2326-6066.CIR-15-0151. Epub 2015 Nov 6.

6.

Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.

De Waele J, Marcq E, Van Audenaerde JR, Van Loenhout J, Deben C, Zwaenepoel K, Van de Kelft E, Van der Planken D, Menovsky T, Van den Bergh JM, Willemen Y, Pauwels P, Berneman ZN, Lardon F, Peeters M, Wouters A, Smits EL.

Oncoimmunology. 2017 Dec 12;7(3):e1407899. doi: 10.1080/2162402X.2017.1407899. eCollection 2018.

7.

Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.

Ishikawa E, Yamamoto T, Matsumura A.

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):321-330. doi: 10.2176/nmc.nmc.ra.2016-0334. Epub 2017 May 24. Review.

8.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
9.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

10.

Immune checkpoint blockade for hematologic malignancies: a review.

Pianko MJ, Liu Y, Bagchi S, Lesokhin AM.

Stem Cell Investig. 2017 Apr 19;4:32. doi: 10.21037/sci.2017.03.04. eCollection 2017. Review.

11.

Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.

Hu ZI, Ho AY, McArthur HL.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):153-164. doi: 10.1016/j.ijrobp.2017.05.029. Epub 2017 May 26. Review.

PMID:
28816141
12.

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP.

Cancer Discov. 2016 Nov;6(11):1230-1236. Epub 2016 Sep 28.

13.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

14.

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells.

Stecher C, Battin C, Leitner J, Zettl M, Grabmeier-Pfistershammer K, Höller C, Zlabinger GJ, Steinberger P.

Front Immunol. 2017 May 22;8:572. doi: 10.3389/fimmu.2017.00572. eCollection 2017.

15.

Immunomodulation: checkpoint blockade etc.

Curry WT, Lim M.

Neuro Oncol. 2015 Nov;17 Suppl 7:vii26-vii31. doi: 10.1093/neuonc/nov174. Review.

16.

Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.

Lucca LE, Hafler DA.

Immunol Rev. 2017 Mar;276(1):9-25. doi: 10.1111/imr.12529. Review.

17.

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.

Hargadon KM, Johnson CE, Williams CJ.

Int Immunopharmacol. 2018 Sep;62:29-39. doi: 10.1016/j.intimp.2018.06.001. Epub 2018 Jul 2. Review.

PMID:
29990692
18.

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.

Ma W, Gilligan BM, Yuan J, Li T.

J Hematol Oncol. 2016 May 27;9(1):47. doi: 10.1186/s13045-016-0277-y. Review.

19.

Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.

Duperret EK, Wise MC, Trautz A, Villarreal DO, Ferraro B, Walters J, Yan J, Khan A, Masteller E, Humeau L, Weiner DB.

Mol Ther. 2018 Feb 7;26(2):435-445. doi: 10.1016/j.ymthe.2017.11.010. Epub 2017 Nov 21.

20.

Genomic correlates of response to immune checkpoint blockade.

Keenan TE, Burke KP, Van Allen EM.

Nat Med. 2019 Mar;25(3):389-402. doi: 10.1038/s41591-019-0382-x. Epub 2019 Mar 6. Review.

PMID:
30842677

Supplemental Content

Support Center